EN DE
Watch Shin Nippon Biomedical Laboratories, Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) fair value: what the stock is really worth

As of Oct 28, 2026: fair value (intrinsic value) of Shin Nippon Biomedical Laboratories, Ltd. stock $10.53, price $9.16, upside +14.9%, quality 46 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Japan

SN Shin Nippon Biomedical Laboratories, Ltd. logo Broad data Nov 17, 2026

Shin Nippon Biomedical Laboratories, Ltd.

SBLOF · US

Rising price, but only slightly cheap (13% below fair value) and weak company: meets 1 of 3 rules.

Get notified free when this changes
Fair value $10.53 · Undervalued 
Rising price (uptrend) 
Healthy Growth (revenue 5y +16.6 %/yr in JPY) 
Solidly profitable · 15.8% net margin (TTM) 
Low debt 
Generates free cash flow 
3.4% dividend yield · Well covered
Ranks above peers (12/14) 
Broad data 
Revenue last quarter +22% vs. a year ago. 
Quality 46/100 
Moderate moat 51/100 · thin data
⚠ Thinly traded
Watch Shin Nippon Biomedical Laboratories, Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$14.93 $8.37 Fair Value $10.53 May 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

42‑month range $8.37 – $14.93 · fair‑value band $5.88 – $14.64 · the $9.16 price screens below the $10.53 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Shin Nippon Biomedical Laboratories in your weekly email

Every Wednesday you see whether Shin Nippon Biomedical Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally.

Show moreShow less

It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies.

The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation delivery technology, discovery of future seeds, and business promotion activities; and development of artificial seed production for Japanese eels.

In addition, it operates hotels accommodations facilities under the Villa Amafuru Oka and HOTEL Freesia names; and develops and operates geothermal and hot spring thermal power plants. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan.

Stock analysis

Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) currently trades at $9.16, while our model-based Fair Value estimate is $10.53, implying the stock looks roughly 13% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $12.88 per share, and 12 of the 26 models we run sit above the $9.16 price.

Bear case: the Dividend Discount group reads lowest at $4.10, and 14 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: $5.88 (bear) to $14.64 (bull), the price of $9.16 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Shin Nippon Biomedical Laboratories, Ltd. reported revenue of ¥32.5B in FY2026 versus ¥17.7B in FY2022, a compound +16.3%/yr. Reported net income was ¥4.6B in FY2026, compounding −10.5%/yr from FY2022.

Key figures

Market cap $381M Small · P/E ratio 12.5 · P/S ratio 1.76 · EPS (TTM) $0.7300 · Dividend yield 3.4% · Net margin 14.0% · Return on equity 13.7% · Return on assets (EBIT) 6.2% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 6% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 15%, SBLOF screens cheaper than that median.

Fair Value models

Bear $5.88 Fair Value $10.53 Bull $14.64
Price $9.16 · Upside +14.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then ($0.2632 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $4.56 $7.60 $12.12 79
Growth DCF $4.49 $7.20 $10.96 77
Residual Income $5.44 $5.96 $6.99 76
All 26 models by family
DCF Models
FCF DCF $4.56 $7.60 $12.12 79
Owner Earnings $5.22 $8.68 $13.81 75
5Y Revenue Exit $3.68 $6.26 $9.65 71
5Y EBITDA Exit $6.90 $12.77 $20.09 73
5Y P/E Exit $7.87 $14.74 $22.53 69
10Y Revenue Exit $3.86 $6.25 $9.73 66
10Y EBITDA Exit $5.88 $10.53 $17.50 66
10Y P/E Exit $6.46 $11.82 $19.32 62
Earnings-Based
Graham-Dodd $4.69 $20.59 $28.18 64
Lynch FV $6.87 $9.81 $12.75 61
PEG = 1.0 $6.87 $9.81 $12.75 57
EPV $2.10 $2.43 $2.70 71
Dividend Discount
Gordon GGM $2.40 $4.27 $5.82 68
DDM Multi-Stage $2.40 $3.93 $4.57 67
Multiples
P/E Multiple $11.37 $15.16 $18.95 63
P/S Multiple $8.79 $11.72 $14.64 58
P/B Multiple $20.88 $27.84 $34.80 55
EV/EBIT $1.75 $3.45 $5.15 63
EV/EBITDA $6.29 $9.50 $12.71 66
EV/Revenue $0.2900 $1.85 $3.41 47
Asset-Based
NCAV (Graham) $3.09 $4.15 $6.19 54
Growth DCF
Growth DCF $4.49 $7.20 $10.96 77
Rev-Margin DCF $3.68 $6.24 $9.49 71
Economic Profit
Residual Income $5.44 $5.96 $6.99 76
ROIC Compounder $2.10 $2.43 $2.70 72
Growth Earnings
Growth-Adj P/E $9.01 $12.88 $16.74 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 38
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 56
Do the profits arrive as real cash?
Financial strength 51
Debt, balance sheet and risk of trouble
Investment 10
Does it invest with discipline instead of growing at any price?
Low Volatility 100
How calm the share price moves, does not count
Price momentum 43
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 69
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+0.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.6%
Start year 2021 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+7.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.5%
Dividend (yield on the price)3.4%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 8%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about +17.1% a year for the price.

Watch SBLOF, get fair value alerts →

Compare Shin Nippon Biomedical Laboratories, Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 151 stocks

Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 46 · Below median
Fair Value upside +14.9% · Top 25%
Profitability
Return on equity (12 months) 13.7% · Top 25%
Return on assets 4.4% · Above median
Net margin (12 months) 15.8% · Top 25%
Operating margin (12 months) 6.6% · Above median
Growth and dividend
Revenue growth (quarter YoY) 21.5% · Top 25%
Dividend yield (12 months) 3.4% · Top 25%
Balance sheet
Debt / equity 0.49× · Highest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (12 months) 12.5× · Cheapest 25%
P/B 1.41× · Cheaper than median
P/S (12 months) 1.79× · Cheaper than median
Price / free cash flow (fiscal year) 20.3× · Cheaper than median
EV/EBITDA 8.9× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)53 · sector 19
FUTURE (revenue growth)100 · sector 40
PAST (return on equity)55 · sector 9
HEALTH (low debt)76 · sector 95
DIVIDEND (yield)69 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Illumina, Inc ILMN $198.00 $227.71 +15% vs SBLOF
WuXi AppTec Co 603259 ¥144.41 ¥164.66 +14% vs SBLOF
IQVIA Holdings IQV $264.73 $291.63 +10% vs SBLOF
Thermo Fisher Scientific Inc TMO $691.33 $686.04 −1% vs SBLOF
Danaher Corporation DHR $229.91 $209.18 −9% vs SBLOF
IDEXX Laboratories, Inc IDXX $700.65 $496.48 −29% vs SBLOF
Lonza Group LONN CHF 670.20 CHF 259.80 −61% vs SBLOF
Mettler-Toledo International Inc MTD $1,727 $655.06 −62% vs SBLOF
Agilent Technologies, Inc A $172.92 $64.20 −63% vs SBLOF
Waters Corporation WAT $453.42 $91.26 −80% vs SBLOF

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shin Nippon Biomedical Laboratories, Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Shin Nippon Biomedical Laboratories, Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/SBLOF

Frequently asked questions

Is Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) overvalued or undervalued?
As of Nov 17, 2026, our model estimates a fair value of $10.53 versus the last price from Oct 28, 2026 of $9.16, about +15% upside (undervalued).
What is the fair value of SBLOF?
Our model-based fair value for Shin Nippon Biomedical Laboratories, Ltd. is $10.53 (as of Nov 17, 2026), built from audited fundamentals. Last price (from Oct 28, 2026): $9.16.
What is the quality score of SBLOF?
Shin Nippon Biomedical Laboratories, Ltd. has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
Our model-based price target is the fair value of $10.53 (as of Nov 17, 2026) from 26 valuation models. Cautious scenario $5.88, optimistic scenario $14.64. It is a calculation from audited fundamentals, not an analyst target.
What is the Shin Nippon Biomedical Laboratories, Ltd. stock forecast for 2026?
Our models put fair value at $10.53, about +15% upside versus the last price from Oct 28, 2026 of $9.16 (undervalued). Cautious scenario $5.88, optimistic scenario $14.64. The calculation is refreshed regularly with new filings.
What is the revenue of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
Shin Nippon Biomedical Laboratories, Ltd. reported trailing-twelve-month revenue of about ¥33.9B (latest available figure, as of Nov 17, 2026).
Does Shin Nippon Biomedical Laboratories, Ltd. pay a dividend?
Shin Nippon Biomedical Laboratories, Ltd. currently shows a dividend yield of 3.43% relative to its recent price (as of Nov 17, 2026).
How much is the dividend of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) and when is the ex-dividend date?
Shin Nippon Biomedical Laboratories, Ltd. pays a dividend of $0.314 per share a year, a dividend yield of 3.4%. The next ex-dividend date is Mar 30, 2027. The payout ratio is 45.6% of earnings. Free cash flow covers the dividend 1.44 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
For today's price to be fair in a discounted-cash-flow model, Shin Nippon Biomedical Laboratories, Ltd. would have to grow free cash flow by 19.6 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 16.6 % per year. As of Nov 17, 2026.
What discount rate (WACC) does the fair value of SBLOF use?
Our models discount Shin Nippon Biomedical Laboratories, Ltd. at 11.2 %: a base by market capitalisation (small), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shin Nippon Biomedical Laboratories, Ltd. that is +19.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) delivered so far?
Over the past 5 years revenue at Shin Nippon Biomedical Laboratories, Ltd. grew 16.6 % a year. The price currently implies free-cash-flow growth of +19.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) growing?
The median revenue growth in the sector is +4.6 % a year. That is the yardstick for the growth priced into Shin Nippon Biomedical Laboratories, Ltd. (+19.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
The free-cash-flow yield on the price is 4.92 %: that much free cash flow Shin Nippon Biomedical Laboratories, Ltd. produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shin Nippon Biomedical Laboratories, Ltd. it is $10.53 per share (as of Nov 17, 2026), against a price of $9.16. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Shin Nippon Biomedical Laboratories, Ltd. stock overvalued or undervalued in 2026?
As of Nov 17, 2026, SBLOF trades below its calculated fair value: price $9.16, fair value $10.53, a gap of about +15% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SBLOF?
No. The price is what the market pays today ($9.16); the fair value is what the company's own numbers justify ($10.53). For Shin Nippon Biomedical Laboratories, Ltd. the two are $1.37 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shin Nippon Biomedical Laboratories, Ltd. worth?
The market values Shin Nippon Biomedical Laboratories, Ltd. at about $381M (market capitalisation, as of Nov 17, 2026). Per share that is $9.16; our models calculate a fair value of $10.53 per share.
What do the bullish and bearish scenarios say about SBLOF?
Our models span a range for Shin Nippon Biomedical Laboratories, Ltd.: cautious scenario $5.88, base $10.53, optimistic $14.64 per share (as of Nov 17, 2026, price $9.16). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SBLOF?
Shin Nippon Biomedical Laboratories, Ltd. trades at a price-to-earnings ratio of 12.5 (as of Nov 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $10.53 is built from several models across several years. Other multiples: P/B 1.4, P/S 1.8, EV/EBITDA 8.9.
How solid is the balance sheet of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
Balance-sheet figures for Shin Nippon Biomedical Laboratories, Ltd. (as of Nov 17, 2026): return on equity 13.7%, debt of 0.49 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is SBLOF from its 52-week high?
Shin Nippon Biomedical Laboratories, Ltd. trades at $9.16, at its 52-week high of $9.16 and 6% above the low of $8.65 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $10.53 is for.
Which stocks are comparable to Shin Nippon Biomedical Laboratories, Ltd.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shin Nippon Biomedical Laboratories, Ltd. stock attractive at the current price?
The data as of Nov 17, 2026: price $9.16, calculated fair value $10.53 (+15%), Quality Score 46/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SBLOF calculated?
We run Shin Nippon Biomedical Laboratories, Ltd. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $10.53 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Shin Nippon Biomedical Laboratories, Ltd. currently trades 13% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
The latest price we hold is from Oct 28, 2026 and stands at $9.16. Our model-based fair value is $10.53, about +15% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shin Nippon Biomedical Laboratories, Ltd. right now?
A fairly wide model range ($5.88 to $14.64) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.

Key figures of Shin Nippon Biomedical Laboratories, Ltd.

How large is the market capitalisation of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
The market capitalisation of Shin Nippon Biomedical Laboratories, Ltd. is $381M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
The price-to-sales ratio of Shin Nippon Biomedical Laboratories, Ltd. is 1.76 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
Earnings per share at Shin Nippon Biomedical Laboratories, Ltd. are $0.7300 (price ÷ EPS = P/E 12.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
The dividend yield of Shin Nippon Biomedical Laboratories, Ltd. is 3.4% (payout 43.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
The net margin of Shin Nippon Biomedical Laboratories, Ltd. is 14.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
The return on equity (ROE) of Shin Nippon Biomedical Laboratories, Ltd. is 13.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
On an EBIT basis the return on assets of Shin Nippon Biomedical Laboratories, Ltd. is 6.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
The operating margin of Shin Nippon Biomedical Laboratories, Ltd. is 6.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
Revenue at Shin Nippon Biomedical Laboratories, Ltd. is growing 21.5% versus a year earlier (3y avg +9.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)?
Earnings per share at Shin Nippon Biomedical Laboratories, Ltd. are growing 309% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Shin Nippon Biomedical Laboratories, Ltd. (SBLOF) carry?
The net debt of Shin Nippon Biomedical Laboratories, Ltd. is ¥22.3B (fiscal year 2026, ≈ 7.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Shin Nippon Biomedical Laboratories, Ltd. in the live analysis

One click puts Shin Nippon Biomedical Laboratories, Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.